RNAi drugs startup Kylin Therapeutics is taking aim at cancer with a drug-delivery technology it recently licensed from Purdue University, according to company officials.
 
However, additional details about the specific indications Kylin expects to pursue are being kept under wraps until the company announces an industry partnership in the next few weeks.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: investigation into the genetics of medulloblastoma, and more

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.